No	Subject	Register number

ASTRA ZENECA

1	Contract 27-08-2020	Ares(2020)4849918
2	1. Draft APA negotiated between AstraZeneca and the Evaluation Committee on 13-08-20	Ares(2020)7907431
3	2. Draft APA negotiated between AstraZeneca and EvaluationCommittee on 13-08-20 2	Ares(2020)7908740

JANSSEN PHARMACEUTICA

4	Contract 21-10-2020	Ares(2020)5806059
		Ares(2021)74830
6	Draft APA negotiated between J&J and the Evaluation Committee 15-09-2020	Ares(2021)106692
7	3. Draft Advanced Purchase Agreement negotiated between J&J and the Evaluation Committee 18-09-2020	Ares(2021)75337
8	4. Draft Advanced Purchase Agreement negotiated between J&J and the Evaluation Committee 25-09-2020	Ares(2021)76546
9	5. Draft Advanced Purchase Agreement negotiated between J&J and the Evaluation Committee 28-09-2020	Ares(2021)76834
10	6. Draft APA negotiated between J&J and the Evaluation Committee 01-10-2020	Ares(2021)106925
	o	Ares(2021)107085
12	8. Draft APA negotiated between J&J and the Evaluation Committee (technical) 06-10-2020	Ares(2021)107537

SANOFI – GSK

13	Contract 18-09-2020	Ares(2020)5034184
14	1. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 27-08-20	Ares(2021)631289
15	2. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 27-08-2020 App	Ares(2021)631900
16	3. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 03-09-20	Ares(2021)632544
17	4. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 04-09-20	Ares(2021)639004
18	5. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 05-09-20	Ares(2021)660367
19	6. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 10-09-20	Ares(2021)660645
20	7. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 11-09-20	Ares(2021)661481
21	8. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 11-09-20 2	Ares(2021)661630
22	9. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 11-09-20 3	Ares(2021)666517
23	10. Draft APA negotiated between Sanofi&GSK and the Evaluation Committee 14-09-20	Ares(2021)666695